相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
Kristen Mathias et al.
ONCOLOGIST (2023)
CD8+T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
Mahrukh A. Huseni et al.
CELL REPORTS MEDICINE (2023)
Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Association between immune-related adverse event timing and treatment outcomes
David Hsiehchen et al.
ONCOIMMUNOLOGY (2022)
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
Nilasha Ghosh et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Emerging therapeutic opportunities for integrin inhibitors
R. J. Slack et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T. Kim et al.
NATURE COMMUNICATIONS (2022)
Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
Taketo Kawai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
Lee S. Nguyen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
T cells specific for α-myosin drive immunotherapy-related myocarditis
Margaret L. Axelrod et al.
NATURE (2022)
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Maria Kfoury et al.
CANCER TREATMENT REVIEWS (2022)
Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis
Shailbala Singh et al.
JCI Insight (2022)
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Paul Johannet et al.
CLINICAL CANCER RESEARCH (2022)
VEDOLIZUMAB PLUS ANTI-PD1 ANTIBODY IN ADVANCED MELANOMA PATIENTS WITH INFLAMMATORY ENTEROCOLITIS
Asad Javed et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Checkpoint Inhibitor-Associated Arthritis A Systematic Review of Case Reports and Case Series
Nilasha Ghosh et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2021)
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis
Shrinivas Bishu et al.
GASTROENTEROLOGY (2021)
Liver biopsy findings in patients on immune checkpoint inhibitors
Justine V. Cohen et al.
MODERN PATHOLOGY (2021)
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors
Marcus Skribek et al.
EUROPEAN JOURNAL OF CANCER (2021)
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
Florentia Dimitriou et al.
EUROPEAN JOURNAL OF CANCER (2021)
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitors-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
Spencer C. Wei et al.
CANCER DISCOVERY (2021)
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery
Shin-Heng Chiou et al.
IMMUNITY (2021)
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
Jennifer A. Lo et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Interleukin-1 in tumor progression, therapy, and prevention
Cecilia Garlanda et al.
CANCER CELL (2021)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series
Corrado Campochiaro et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
Nicholas L. Bayless et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
Samantha N. Champion et al.
MODERN PATHOLOGY (2020)
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita et al.
NATURE (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
Charles Dolladille et al.
JAMA ONCOLOGY (2020)
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M. Luoma et al.
CELL (2020)
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma
Sabino Strippoli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Efficacy and immune-related adverse event associations in avelumab-treated patients
Karen Kelly et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Takeshi Tanoue et al.
NATURE (2019)
Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Changhua Ji et al.
CLINICAL CANCER RESEARCH (2019)
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
Melvyn T. Chow et al.
IMMUNITY (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials A Systematic Review and Meta-analysis
Yucai Wang et al.
JAMA ONCOLOGY (2019)
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Fiamma Berner et al.
JAMA ONCOLOGY (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs
Arianna Draghi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-47 and anti-PD1 antibodies
Christopher C. Frohne et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
Alexander T. Faje et al.
CANCER (2018)
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C. Leonardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab
Susan C. Scott et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Yannick Simoni et al.
NATURE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
Elizabeth H. Byrne et al.
CANCER (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T Lymphocytes
Wong Yu et al.
IMMUNITY (2015)
Challenges of Guarantee-Time Bias
Anita Giobbie-Hurder et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
HJ Kwon et al.
ANNALS OF INTERNAL MEDICINE (2003)